Exelixis
EXEL
#1695
Rank
A$15.66 B
Marketcap
$54.84
Share price
-3.83%
Change (1 day)
57.41%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.45. In 2022 the company made an earnings per share (EPS) of $0.90 a decrease over its 2021 EPS that were of $1.17.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.43-52.37%
2022$0.90-22.97%
2021$1.17100%
2020$0.58-65.09%
2019$1.68-53.91%
2018$3.64333.96%
2017$0.84-260.61%
2016-$0.52-58.75%
2015-$1.26-42.45%
2014-$2.205.3%
2013-$2.0943.48%
2012-$1.45-264.29%
2011$0.89-165.88%
2010-$1.34-32.54%
2009-$1.99-17.65%
2008-$2.4275.86%
2007-$1.38-25.64%
2006-$1.858.33%
2005-$1.71-42.86%
2004-$2.9930.34%
2003-$2.29-5.23%
2002-$2.42-0.65%
2001-$2.43-51.88%
2000-$5.06

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.53 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.03 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.88 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.28 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.37 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.27 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.94 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$15.81-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.33-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA